Immix Biopharma (IMMX) news

Immix Biopharma, Inc.: H.C. Wainwright raises target price to $25 from $20

H.C. Wainwright has raised its price target for Immix Biopharma (IMMX) to $25 from $20, reflecting positive development pipeline and financial positioning. The updated target aligns with the broader analyst consensus, which currently stands at a "Buy" rating based on evaluation of seven analysts .…

Immix Biopharma Inc: Needham initiates coverage with buy rating; target price $21

Needham & Company has initiated coverage of Immix Biopharma Inc (NASDAQ: IMMX), assigning a "Buy" rating and target price of $21 . The firm highlighted the company’s progress in its therapeutic pipeline and the potential for near-term catalysts, including data readouts from ongoing clinical trials.…

Immix Biopharma - Richard Graydon terminated from Immix Biopharma as of July 17, 2026 - SEC filing

Immix Biopharma Inc: BofA Global Research initiates coverage with buy rating; price objective $27

BofA Global Research has initiated coverage on Immix Biopharma Inc. (NASDAQ: IMMX) with a "Buy" rating and a price target of $27.00 per share, citing promising developments in the company’s lead candidate, NXC-201, for the treatment of relapsed/refractory AL amyloidosis, a rare and life-threatening…

Immix Biopharma closes $150M offering of stock

Immix Biopharma (NASDAQ: IMMX) has completed a $150 million underwritten offering of common stock, pricing 16,778,524 shares at $8.94 per share. The offering, announced on May 21, 2026, is expected to generate significant capital to support the company’s ongoing clinical development of its lead…